TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07157423: Safety of Eptacog Alfa in Severe Postpartum Haemorrhage in India: A Phase IV Interventional Study

Sponsor: Novo Nordisk A/S · Phase: PHASE4 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 64 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$5,471,360

Rescue Site Savings

+$3,612,160

Unlock Full NCT07157423 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07157423 Rescue Dossier →